Related Experiment Video
Updated: Jun 22, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New Therapeutic Horizons for Advanced or Metastatic Penile Cancer
Nicholas Simon1, Saad Atiq2, Guru Sonpavde3
1Department of Oncology, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 12C432B, Bethesda, MD 20892, USA.
Abstract:
Penile cancer is a rare malignancy with a poor prognosis. Studies with single-agent immune checkpoint inhibitors (ICIs) have demonstrated efficacy, but response rates are low. Studies combining ICIs with both chemotherapy and targeted therapy are ongoing. Up to 50% of penile cancer cases are associated with human papillomavirus (HPV). HPV-targeting therapies, such as HPV-targeting vaccines and T-cell receptor therapies, are an area of active investigation. Penile cancer cells also express cell surface antigens that may be targeted by the emerging class of antibody-drug conjugates.
Insights
Penile cancer is rare but challenging. Investigating new treatments like immune checkpoint inhibitors, HPV therapies, and antibody-drug conjugates offers hope for improved outcomes in this malignancy.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Penile cancer is a rare malignancy with a poor prognosis.
- Single-agent immune checkpoint inhibitors (ICIs) show limited efficacy in penile cancer.
- Human papillomavirus (HPV) is associated with up to 50% of penile cancer cases.
Purpose of the Study:
- To explore novel therapeutic strategies for penile cancer.
- To investigate the potential of combining ICIs with chemotherapy and targeted therapy.
- To evaluate emerging treatments targeting HPV and cell surface antigens.
Main Methods:
- Review of current and ongoing clinical studies.
- Analysis of therapeutic targets including ICIs, HPV, and cell surface antigens.
- Exploration of combination therapies and novel agents like antibody-drug conjugates.
Main Results:
- Current ICI monotherapy response rates are low.
- Combination therapies involving ICIs, chemotherapy, and targeted agents are under investigation.
- HPV-targeting therapies and antibody-drug conjugates represent promising avenues.
Conclusions:
- Penile cancer treatment requires novel approaches beyond single-agent ICIs.
- Targeting HPV and utilizing antibody-drug conjugates show significant therapeutic potential.
- Further research into combination therapies is crucial for improving patient outcomes.
More Related Videos
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...